Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphoma × orelabrutinib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, B-Cell, Marginal Zone 13 Lymphoma, Mantle-Cell 9 Lymphoma, Large B-Cell, Diffuse 7 Leukemia, Lymphocytic, Chronic, B-Cell 2 Recurrence 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Lymphoma 1 Hematologic Neoplasms 1

Interventions

Cyclophosphamide 391 Rituximab 341 Etoposide 198 Vincristine 184 Filgrastim 177 Doxorubicin 174 Prednisone 148 Radiotherapy 140 Cytarabine 139 fludarabine phosphate 124 Methotrexate 118 Melphalan 113 Peripheral Blood Stem Cell Transplantation 109 fludarabine 103 Busulfan 84 Dexamethasone 81 Carmustine 65 Granulocyte Colony-Stimulating Factor 63 Tacrolimus 59 Gemcitabine 59 Mycophenolic Acid 56 Whole-Body Irradiation 55 Bendamustine Hydrochloride 55 Antilymphocyte Serum 55 Lenalidomide 53 Ifosfamide 53 Cyclosporine 52 Bortezomib 50 Methylprednisolone 43 Leucovorin 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡